A vaccine composition for preventing toxoplasmosis induced by Toxoplasma gondii infection comprising SAG1-VLP

摘要

The present invention provides a pharmaceutical vaccine composition and an veterinary medicine vaccine composition for preventing or improving toxoplasmosis (Toxoplasmosis) caused by toxoplasmosis infection, comprising SAG1-VLP as an active ingredient. More specifically, SAG1-VLP (SAG1-Virus like particle) containing the SAG1 protein of Toxoplasmosis and influenza A virus matrix protein 1 is a parasite that causes toxoplasmosis, a zoonotic disease ( Toxoplasma gondii : T. gondii ) by generating a specific antibody and forming immunity, thereby inhibiting and blocking the infection of Toxoplasmosis, and thus has the effect of preventing infection of Toxoplasmosis. It is useful as a vaccine composition and a vaccine composition for veterinary medicine.